• M Sluga, R Windhager, S Lang, H Heinzl, P Krepler, F Mittermayer, M Dominkus, A Zoubek, and R Kotz.
• Department of Orthopaedics, University of Vienna, Vienna, Austria. maria.sluga@akh-wien.ac.at
• Eur J Surg Oncol. 2001 Sep 1; 27 (6): 569-73.

AimsThe treatment of patients suffering from Ewing's sarcoma has changed over the last three decades. We report the analyses, significant prognostic factors, interdisciplinary approach and development of therapy in one institution in Austria.MethodsOne hundred and forty-two patients treated for Ewing's sarcoma between 1949 and 1994 were reviewed. Median follow-up was 8.5 years. Fifty-six patients were treated between 1949 and 1980 (group 1), and 86 patients between 1981 and 1994 (group 2). Patients in group 1 were treated with polychemotherapy. Patients in group 2 were treated with a neoadjuvant CESS (Cooperative Ewing's Sarcoma Study) regimen. In group 1, 24 patients underwent biopsy only, 32 patients had a definitive operation, 48 patients received either radiation therapy only or additional radiation therapy compared with in group 2: 6, 80 and 44 cases, respectively.ResultsFive-year overall survival (OS) increased from 27% to 57%. Significant prognostic factors for OS were pre-operative metastases (P=0.0001), tumour location (P=0.0048), type of chemotherapy (P=0.002) and response to chemotherapy (P=0.0004). Chemotherapy (P=0.037), tumour location (P=0.0017) and metastases at diagnosis (P=0.0025) were significant.ConclusionThe most effective treatment of Ewing's sarcoma is chemotherapy.Copyright 2001 Harcourt Publishers Limited.

35 keywords...

hide…